Study to Evaluate the Safety and Tolerability of TT-01488 in Patients With B-Cell Malignancies

Inclusion Criteria:

1. Men and women ≥ 18 years of age with histologically or cytologically confirmed R/RB-NHL, including but not limited to chronic lymphocytic leukemia/small lymphocyticleukemia (CLL/SLL), Waldenström macroglobulinemia (WM), follicular lymphoma (FL),marginal zone lymphoma (MZL), diffuse large-b-cell lymphomas (DLBCL), and transformedlymphoma who failed or are intolerant to ≥ 1 prior standard of care regimens. Notes:

• Patients with prior treatment of BTK inhibitors are eligible
• Patients with low grade lymphoma must be progressing and requiring treatment:
• Patients with CLL must have disease requiring treatment as specified in 2018IWCLL Guidelines (Appendix 5)
• Patients with B-cell NHL must have measurable disease per 2014 LuganoClassification (Appendix 6)
• Patients with WM must have minimum serum immunoglobulin M (IgM) level of ≥ 2times the upper limit of normal (ULN)

2. Body weight ≥ 40 kg
3. Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2
4. Adequate organ function, defined by the following laboratory parameters:

• Hematologic:
• Absolute neutrophil count (ANC) ≥ 750/ul, unless due to bone marrowinvolvement due to disease
• Platelets ≥ 50,000/ul without transfusion within 7 days
• Hemoglobin ≥ 80 mg/dl without transfusion within 7 days
• Coagulation:
• Prothrombin time (PT) ≤ 1.5 × ULN
• Activated partial thromboplastin time (aPTT) ≤ 1.5 × ULN
• Renal function: o Creatinine clearance ≥ 60 mL/min estimated glomerular filtration rate based onCockcroft-Gault formula or 24-hour urine collection
• Liver function:
• Total bilirubin ≤ 1.5 × ULN (unless due to Gilbert's disease)
• Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≤ 2.5 ×ULN unless disease-related

5. Agreement to use contraception during the study and until at least 6 months after thelast dose of study drug if sexually active and able to bear children
6. Willing and able to participate in all required evaluations and procedures in thestudy protocol including swallowing tablets without difficulty
7. Ability to understand the purpose and risks of the study and provide signed and datedinformed consent and authorization to use protected health information (in accordancewith national and local subject privacy regulations)

Exclusion Criteria:

1. Women who are pregnant or lactating
2. Prior malignancy, except for adequately treated basal cell or squamous cell skincancer, in situ cervical cancer, or other cancer from which the subject has beendisease-free for at least 2 years or which will not limit survival to < 2 years (Note:these cases must be discussed with the Medical Monitor and/or Investigator)
3. A life-threatening illness, medical condition, or organ system dysfunction which, inthe investigator's opinion, could compromise the subject's safety, interfere with theabsorption or metabolism of TT-01488, or put the study outcomes at undue risk
4. Significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias,congestive heart failure, or myocardial infarction within 6 months of screening, orsignificant screening ECG abnormalities including left bundle branch block, 2nd degreeAV block type II, 3rd degree block, bradycardia, and corrected QT interval usingFridericia's Formula (QTcF) > 470 msec, or any Class 3 or 4 cardiac disease as definedby the New York Heart Association Functional Classification
5. Malabsorption syndrome, disease significantly affecting gastrointestinal function, orresection of the stomach or small bowel or ulcerative colitis, symptomaticinflammatory bowel disease, or partial or complete bowel obstruction
6. Any immunotherapy, , radiotherapy (limited-field radiation for palliation within 7days), or experimental therapy within 4 weeks, or 5-half lives for chemotherapy andsmall molecule agents (whichever is shorter), before first dose of study drug (corticosteroids for disease-related symptoms allowed but require 1-week washoutbefore study drug administration)
7. History of allogeneic or autologous stem cell transplant (SCT) or chimeric antigenreceptor-modified T-cell (CAR-T) therapy within the past 60 days or with any of thefollowing:

• Active graft versus host disease (GvHD);
• Cytopenias from incomplete blood cell count recovery post-transplant;
• Need for anti-cytokine therapy for toxicity from CAR-T therapy; residual symptomsof neurotoxicity > Grade 1 from CAR-T therapy;
• Ongoing immunosuppressive therapy

8. Concomitant use of prohibited medications(Section 6.4.2), including:

• Therapeutic doses of warfarin sodium (Coumadin®) or any other coumarin-derivativeanticoagulants
• Medications with known risk to cause QT prolongation or Torsades de pointes
• Strong CYP3A inhibitors and inducers (must be discontinued for at least 14 daysor 5 half-lives, whichever is longer, before study treatment)
• Proton pump inhibitors, histamine-2 blockers (H2 blockers), and locally actingantacids (Note: For patients who are dependent upon this class of medications,patients may be considered after consulting with the study investigator andSponsor. See Section 6.4.2 for more details).

9. Central nervous system involvement by lymphoma
10. Grade ≥ 2 toxicity (other than alopecia) continuing from prior anticancer therapy,including radiation
11. Known history of Human Immunodeficiency Virus (HIV) or active infection withCytomegalovirus (CMV), Hepatitis C Virus (HCV) or Hepatitis B Virus (HBV), or anyuncontrolled active systemic infection
12. Major surgery within 4 weeks before first dose of study drug